Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lantern Pharma ( (LTRN) ) has provided an announcement.
Lantern Pharma reported its fourth-quarter and full-year 2025 results on March 30, 2026, highlighting a year of clinical validation and strategic expansion across its AI-driven oncology pipeline, while reducing operating expenses by 19% year over year and ending 2025 with about $10.1 million in cash and securities. In 2025 the company advanced its LP-300 Phase 2 HARMONIC trial in never-smoker NSCLC with completed enrollment in Japan and promising early U.S. data, completed Phase 1a for LP-184 with a 48% clinical benefit rate, secured FDA IND clearance for STAR-001 in pediatric CNS cancers through subsidiary Starlight Therapeutics, gained additional orphan drug designation for LP-284 in soft tissue sarcomas, and launched global AI initiatives including an AI Center of Excellence in India and the withZeta.ai platform, which entered beta testing with more than 25 external partners.
The most recent analyst rating on (LTRN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
The score is primarily held down by weak financial performance (no revenue, persistent losses, and significant cash burn with a shrinking equity base). Offsetting this, the latest earnings call cited notable clinical/regulatory milestones and AI platform progress, while technicals are neutral-to-slightly positive but not strong enough to outweigh financing and profitability risks.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc., based in Dallas and listed on Nasdaq under the symbol LTRN, is a clinical-stage biopharmaceutical company focused on oncology. The company leverages its proprietary RADR artificial intelligence and machine learning platform, along with the withZeta.ai multi-agentic AI co-scientist system, to discover, develop and reposition cancer drug candidates across solid tumors, blood cancers and rare pediatric cancers, targeting an estimated market potential of more than $15 billion annually.
Average Trading Volume: 172,840
Technical Sentiment Signal: Sell
Current Market Cap: $12.53M
Find detailed analytics on LTRN stock on TipRanks’ Stock Analysis page.